Company Information
Industry 制造业
Company Introduction 成立于2007年,是一家以治疗感染性疾病为核心,拥有全球自主知识产权和国际竞争力的创新型生物医药企业,致力于发现、开发和商业化针对未满足临床需求的创新药物。自成立之初,公司一直秉承“以良药求良效”的理念,聚焦全球日益严重的细菌耐药性问题,以解决临床难题、差异化创新为核心竞争力,目标为临床最常见和最严重的耐药菌感染提供更有效和更安全的治疗选择。 公司于中国和美国两地建立了研发中心,拥有国际化的核心研发团队。公司的研发团队具有多年国际创新药研发和管理工作经验,曾主导或参与了多个已上市抗感染新药的开发。公司坚持自主研发,深耕专业化细分领域,在公司内部建立了一体化的抗菌新药研发体系,覆盖创新药的早期设计与筛选、临床前评价、全球临床开发、注册申报和生产管理等完整新药开发环节。公司以国际经验和标准,采用中美同步新药开发的运营模式。 公司首个抗菌药产品康替唑胺片是公司自主设计和开发的新一代噁唑烷酮类抗菌药,可用于治疗多重耐药革兰阳性菌引起的感染。康替唑胺已完成了中国I、II和III期临床试验,澳大利亚I期及美国II期临床试验,于2021年6月1日通过国家药品监督管理局优先审评审批程序批准上市,并于2021年12月通过国家医保谈判纳入2021年国家医保目录(乙类),拓展适用人群到儿童的临床试验正在进行中[1]。康替唑胺在中国的临床试验实施了多项开创性举措,为中国未来创新抗菌药领域提升临床试验标准及产品质量奠定了坚实的基础。MRX-4为康替唑胺的水溶性前药,在体内转化为康替唑胺发挥疗效,MRX-4序贯康替唑胺的全球多中心III期临床试验正在进行中。MRX-8为用于治疗多重耐药革兰阴性菌感染药物,美国的I期临床试验已经完成,中国I期临床试验正在进行中[2]。除上述三个已进入临床阶段和/或商业化阶段的核心产品外,公司还有多项处于临床前阶段的抗耐药菌新药,肾癌、肾炎药物以及抗新冠药物管线。
Main Business 发现、开发和商业化未满足临床需求的创新药物。
Legal Representative ZHENGYU YUAN(袁征宇)
Top Executives
董事长:袁征宇
董事:赵雅超,吉冬梅,李峙乐
独立董事:周伟澄,黄寒梅,陈燕桂
Top 5 Shareholder
Shareholder name Nature Holding Date
Genie Pharma限售股10.92%30/09/2024
MicuRx(HK)Limited限售股10.80%30/09/2024
Best Idea International Limited限售股10.49%30/09/2024
JSR Limited限售股5.89%30/09/2024
华盖资本有限责任公司-北京华盖信诚远航医疗产业投资合伙企业(有限合伙)流通A股4.47%30/09/2024
Company Secretary 李峙乐
Solicitors 北京市嘉源律师事务所
Auditors 致同会计师事务所(特殊普通合伙);普华永道中天会计师事务所(特殊普通合伙)
Tel No 021-50900550
Fax No 021-61101898
Website www.micurxchina.com
Email 688373@micurxchina.com
Company Address
Register: 中国(上海)自由贸易试验区爱迪生路53号1幢1-4层101、2幢
Office: 中国(上海)自由贸易试验区爱迪生路53号1幢1-4层101、2幢
Listing Date 05/08/2022
Shares Capital
Shares Capital: 655,210,084
Total A Share: 655,210,084
Listed A Share: 365,651,733
Non-tradable A Share: 289,558,351
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.640
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 1.273
Market Capitalization(RMB) 2.007B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.